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SUMMARY
Our objective was to identify predictors of severe acute respiratory infection in hospitalized 
patients and understand the impact of vaccination and neuraminidase inhibitor administration on 
severe influenza. We analyzed data from a study evaluating influenza vaccine effectiveness in two 
Michigan hospitals during the 2014–2015 and 2015–2016 influenza seasons. Adults admitted to 
the hospital with an acute respiratory infection were eligible. Through patient interview and 
medical record review, we evaluated potential risk factors for severe disease, defined as ICU 
admission, 30-day readmission, and hospital length of stay. Two hundred of 1072 participants had 
PCR-confirmed influenza. Frailty score, Charlson score, and tertile of prior-year health care visits 
were associated with length of stay. Charlson score >2 (OR:1.6[1.0, 2.4]) was associated with ICU 
admission. Highest tertile of prior-year visits (OR:0.4[0.2, 0.7]) was associated with decreased 
ICU admission. Increasing tertile of visits (OR: 1.4[1.2, 1.8]) was associated with 30-day 
readmission. Frailty and prior-year health care visits were associated with 30-day readmission 
among influenza-positive participants. Neuraminidase inhibitors were associated with decreased 
length of stay among vaccinated participants with influenzaA (HR:1.6 [1.0, 2.4]). Overall, frailty 
and lack of prior-year health care visits were predictors of disease severity. Neuraminidase 
inhibitors were associated with reduced severity among vaccine recipients.
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INTRODUCTION
It is widely recognized that seasonal respiratory illness, which peaks in fall and winter in 
temperate regions, is associated with corresponding peaks in doctor’s office visits and 
hospital admissions [1,2]. Numerous respiratory pathogens are associated with 
hospitalization; notably, influenza, human metapneumovirus, respiratory syncytial virus, 
rhinovirus, and parainfluenza virus; all of which cause similar symptoms [3]. However, 
influenza-associated illness accounts for a substantial proportion of these medical events 
[2,4]. Influenza is a viral pathogen that causes an estimated 12,000 to 56,000 deaths in the 
United States annually [5]. Influenza-related severe outcomes, such as death, ICU 
admission, or the need for invasive mechanical ventilation, generally occur in elderly 
individuals or individuals with numerous comorbidities; however, previously healthy adults 
are also at risk for serious illness [6,7].
During the 2009 influenza A(H1N1) pandemic, individuals thought to be at low risk for 
severe influenza, such as those under the age of 65 and without recognized underlying 
conditions, were hospitalized at a higher than expected rate [8]. During the pandemic, 
previously unknown risk factors for influenza severity were identified with morbid obesity 
being one of the most consistently identified factors [9,10]. In post-pandemic seasons the 
age of those hospitalized for influenza A(H1N1)pdm09 infection increased along with an 
increase in the severity of influenza-related pneumonia [11–13]. There was, paradoxically, a 
corresponding decrease in the use of antiviral treatment initially, though rates of treatment 
have since risen [13,14]. With the continued circulation of the A(H1N1) pandemic strain 
along with A(H3N2) and B viruses it is critical to identify and monitor groups at risk for 
severe disease in order to optimize strategies, including use of neuraminidase inhibitors and 
vaccine prioritization when the vaccine supply is limited, to prevent adverse outcomes.
In order to identify predictors of influenza and acute respiratory illness (ARI) severity and, 
specifically, to understand the impact of vaccination and neuraminidase inhibitor 
administration on illness severity, we present data from adults hospitalized with ARI from 
two hospitals in Southeast Michigan over the 2014–2015 and 2015–2016 influenza seasons. 
Severe outcomes evaluated include ICU admission, length of stay (LOS), and 30-day 
readmission.
METHODS
Participant enrollment, interview and specimen collection
Participants were adults hospitalized for ARI at University of Michigan Hospital (UMH, 
Hospital A) in Ann Arbor, Michigan and Henry Ford Hospital (HFH, Hospital B) in Detroit. 
Enrollment occurred from November 5th 2014 to March 6th 2015, and from January 11th 
2016 to April 15th 2016. Staff reviewed electronic medical records (EMRs) daily to identify 
newly admitted patients (≤72 hours) with ARI as previously described [15]. Eligible 
participants were approached, and they or their proxy provided written consent for 
participation in the study. All study procedures were approved by the Institutional Review 
Boards of the University of Michigan Medical School and the Henry Ford Health System.
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Patients were interviewed at enrollment to collect information about demographics, 
influenza vaccination status, general health status, illness characteristics, and subjective 
assessment of frailty (unexplained >10 pounds weight loss [yes/no], little energy for desired 
activities [yes/no], difficulty walking 100 yards [no difficulty…unable to do], difficulty 
carrying 10 pounds [no difficulty…unable to do] and frequency of low/moderate activity 
[more than once/week…hardly ever/never]). Number of health care encounters in the past 
year and evidence of neuraminidase inhibitor prescription from the study hospital admission 
were extracted from EMRs. Information about comorbid health conditions were also 
extracted to calculate the Charlson Comorbidity Index (CCI) for each patient. The following 
outcome variables were collected from the EMR: death, ICU admission, ventilator use, 
length of stay, and 30-day readmission. Outcomes that were experienced by more than 10 
influenza-positive participants, including ICU admission, length of stay, and 30-day 
readmission, were used in models.
Laboratory Methods
Nasal and throat swabs collected at enrollment were combined and tested for influenza 
viruses using reverse transcriptase polymerase chain reaction (RT-PCR). All primers, probes 
and protocols were developed and provided by the Influenza Division of the CDC. They 
were designed for detection of universal influenza A and B, and for subtype and lineage 
identification. All tests were performed in the investigators’ laboratory at the University of 
Michigan School of Public Health.
Influenza Vaccination Status
Individuals were considered vaccinated if they had documentation or plausible self-report of 
influenza vaccine receipt ≥14 days before illness onset. Documented vaccination status was 
determined based on documentation from the EMR or state immunization registry. Plausible 
self-report was defined as reporting both the approximate date and location of vaccination. 
Individuals were considered unvaccinated if they had no evidence of documentation of 
vaccination and self-reported no vaccination. Participants were excluded if they had an 
incomplete self-report of vaccination (e.g. missing date or location) and no additional 
documentation or if they were vaccinated <14 days before illness onset.
Statistical Methods
CCI scores were categorized as 0, 1, 2, or 3 or greater; high CCI was defined as greater than 
2. Frailty was defined as the presence of up to 5 dichotomized variables taken from the 
enrollment interview that were summed and weighted by the number of questions answered, 
as a few participants either refused to answer or answered “don’t know” to either one or two 
of the frailty questions [15,16]. Total prior-year health care visits were defined as all inpatient 
and outpatient visits for any reason to a UM or HF Health System affiliated clinic in the 
previous year. Tertiles of prior year health care visits among all participants were calculated, 
and the variable was expressed as either 0 visits, or visits falling into the first (1–8 visits), 
second (9–21 visits), or third (≥22 visits) tertile. Long length of stay was defined as length of 
stay of >8 days. When used as a continuous outcome, LOS was log-transformed and beta 
coefficients were analyzed as percent change of LOS.
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Participants were compared in frequency models using Pearson χ2 test or Fisher’s exact test. 
Firth’s penalized logistic regression models were used to predict the odds of severe illness 
by various risk factors. Firth’s method was used to reduce small-sample bias and improve 
model fit in the context of quasi-separation. Hospital site (UMH or HFH), sex, age (18–49, 
50–64, 65+), frailty score, and CCI>2 were included in adjusted models a priori. Tertile of 
prior-year health care visits was included based on their significance in univariate models; 
this variable was modeled categorically for the outcomes of ICU admission and hospital 
length of stay and ordinally for 30-day readmission due to the monotonic relationship 
between these variables. For analyses restricted to influenza A positive individuals, influenza 
A subtype, influenza vaccination were included as adjustment factors. Cox proportional 
hazard models, censoring on death, were used to estimate the impact of antiviral treatment 
on hospital length of stay. Neuraminidase inhibitor administration was modeled as a time 
varying covariate indicating the day in the hospital admission when participants were 
treated. The models were adjusted for covariates associated with increased hospital length of 
stay in the risk factor analysis, weighted frailty score and tertile of prior-year health care 
visits. All statistics were completed using SAS (release 9.4, SAS Institute). Statistical 
significance was defined as a 95% confidence interval that did not include the null value.
RESULTS
Demographics and Outcomes by Influenza Status
We enrolled 1199 adults with ARI; 727 from the 2014–2015 season and 472 from the 2015–
2016 season. Eighty (7%) hospitalizations were excluded due to missing or incomplete 
information on vaccination status, influenza status, or Charlson score, leaving 1119 
participants in the analysis.
Two-hundred sixteen (19%) participants had PCR-confirmed influenza virus infection. 
Influenza-positive participants were significantly less likely to have received influenza 
vaccines (Table 1). Half of participants had a CCI >2 but this percentage was significantly 
lower in individuals with influenza (41.2%) compared to those testing negative (52.2%). 
Among influenza positive participants there were 2 deaths, 22 ICU admissions, 10 invasive 
ventilations and 19 instances of long LOS (>8 days); these outcomes were observed in 
similar frequencies between the influenza positive and negative populations. Thirty-day 
readmission was significantly less frequent among influenza-positive participants compared 
to those testing negative (Table 1).
One-hundred and eleven participants were infected with influenza A(H3N2) viruses, 90 with 
influenza A(H1N1)pdm2009 and 15 with influenza B viruses; models restricted to 
influenza-positive individuals excluded individuals with influenza B virus infection. There 
was a higher frequency of influenza A(H1N1)pdm09 infection among participants who were 
18–49 years old (37% with H1N1 vs. 26% with H3N2, p=0.10), though this difference was 
not statistically significant (Table 2). CCI (p=0.02), tertile of prior year health care visits 
(p=0.05) and vaccination status (p=0.02) were associated with influenza A subtype; 
individuals with a CCI of 0, no health care visits in the prior year and who were 
unvaccinated were more frequently infected with influenza A(H1N1)pdm09 (Table 2). A 
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higher percentage of participants infected with H1N1 were admitted to the ICU, put on an 
invasive ventilator, and had LOS >8 days compared to those infected with H3N2 (Table 2).
Models Predicting Severe ARI and Influenza-associated ARI
Higher frailty and increased tertile of prior-year health care visits were associated with 
increased 30-day readmission among influenza-positive participants (Table 3). Individuals 
with the highest tertile of prior-year health care visits had decreased odds of ICU admission 
compared to those with no prior-year visits regardless of influenza status (Table 3). Frailty 
score was associated with longer LOS among all participants but not among participants 
with influenza-associated ARI (Table 3).
Neuraminidase Inhibitor Prescription
One hundred fourty-seven (68%) influenza-positive participants were treated with 
neuraminidase inhibitors. Treatment varied by enrollment hospital; over 75% of influenza-
positive patients from Hospital A were treated compared to only 57% from Hospital B 
(p=0.01) (Table 4). Neuraminidase inhibitor administration also varied by time from illness 
onset to admission; 73% of participants admitted within two days were treated compared to 
59% of those admitted later (p=0.02) (Data not shown). Median length of stay was lower 
among those with timely antiviral treatment (2.0 days) compared to those with late antiviral 
treatment (3.0 days) or no treatment (3.0), however the median length of stay did not vary 
significantly.
Clinical testing for influenza varied significantly by enrollment hospital, 74% of influenza-
positive participants from Hospital B by research testing received a clinical influenza test 
compared to 90% from Hospital A. Only 10% of participants from either hospital without a 
clinically positive influenza test were treated with neuraminidase inhibitors (Data not 
shown).
The influenza-positive population was further stratified by vaccination status. Vaccinated 
individuals who were treated with neuraminidase inhibitors had a significantly reduced LOS 
(HRdischarge:1.6, 95% CI: 1.0, 2.4], p=0.04) compared to those who were untreated (Table 
5). Other severe outcomes were not evaluated in this analysis due to insufficient sample size.
DISCUSSION
Our study identified risk factors for severe influenza-associated ARI and all-cause ARI 
among hospitalized patients over two influenza seasons. Given that viral etiology is often 
unknown at admission when many treatment decisions are made, it is important to 
understand severity of ARI of all causes in the hospital. Of note, 65% of participants where 
tested clinically for influenza and the majority of these tests were initiated the day of or the 
day after hospital admission. Despite the timely testing, it may take many hours for PCR 
results to be available to the clinician and rapid influenza tests are known for their low 
specificity. For these reasons, treatment decisions should be made before viral etiology is 
known in most cases. Higher frailty score was associated with longer LOS, and having 0 
prior-year health care visits was associated with higher odds of ICU admission. Frailty is a 
well-known predictor of severity and death, especially among the elderly, though many 
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studies do not consider frailty when studying influenza severity [17–19]. The increased 
severity among those without prior-year health care visits may indicate that individuals who 
are unlikely to seek care present to the hospital with the most severe illnesses. Increased 
health care visits over the prior year were also associated with increased, rather than 
reduced, 30-day readmission indicating that 30-day readmission may be, in part, a measure 
of underlying chronic conditions [20].
We evaluated the impact of vaccination and neuraminidase inhibitor administration on 
influenza severity. Neuraminidase inhibitors were significantly associated with decreased 
LOS among vaccinated individuals only after stratification by vaccination status. While the 
association between neuraminidase inhibitor administration and reduced influenza severity 
has been emphasized, the interaction between vaccination and neuraminidase inhibitors is 
not well documented or understood [21,22]. Though this result offers an interesting potential 
relationship between antiviral treatment, vaccination, and influenza severity, the extremely 
small sample size in this stratified population necessitates repeated demonstration of this 
association in larger, future studies.
In light of this result and other evidence in the literature, it is critical that hospitalized 
influenza-positive patients are treated with neuraminidase inhibitors [22,23]. We found that 
just 67% of participants with PCR-confirmed influenza were prescribed neuraminidase 
inhibitors though treatment is recommended for all hospitalized patients with suspected or 
confirmed influenza. Treatment varied significantly by enrollment hospital; over 40% of 
influenza-positive participants at Hospital B did not receive neuraminidase inhibitors, 
compared to 23% at Hospital A. While all participants are tested for influenza by our 
research team, not every patient receives a clinical influenza test during their hospital stay. 
This appeared to impact treatment decisions, as very few individuals without a clinically 
positive influenza test were treated despite the recommendation that hospitalized individuals 
with suspected influenza be treated empirically.
These numbers indicate a need to continue public health messaging directed at nurses and 
physicians to encourage empiric treatment and to keep influenza on the list of possible 
diagnoses during influenza season. Additionally, participants were less likely to be treated if 
they were admitted to the hospital >2 days after symptom onset. This reflects the widely 
held opinion that antiviral drugs are only effective within 2 days of symptom onset. While 
studies have shown that effectiveness is higher when neuraminidase inhibitors are given 
promptly, there is evidence among hospitalized patients with influenza that treatment within 
5 days of symptom onset improves survival [21,22,24].
Continued interest in the potential for vaccination to reduce influenza severity stems from 
the vaccine effectiveness (VE) estimates from the 2014–15 influenza season, which 
primarily consisted of influenza A viruses that were antigenically drifted from the Northern 
Hemisphere vaccine strains [15,25]. VE estimates from the 2014–15 season were higher in 
hospital studies than in ambulatory care studies, where they were not significantly different 
from zero [15,26,27]. This could indicate that influenza vaccination reduces severity as well as 
incidence; this hypothesis has been previously evaluated but results are mixed [28–31]. We 
did not find an association between severity and vaccination. Observational studies of 
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severity, such as ours, as well as evaluations of interventions such as vaccination are often 
impacted by confounding by indication and other challenges.
Overall, the small number of influenza-positive participants in this study led to reduced 
power, which may explain the few significant predictors of influenza severity. The in-
hospital observational nature of the study complicated our ability to study some commonly 
used severity endpoints such as mechanical ventilation and death. Additionally, selection 
into this study depended on hospital admission prior to enrollment, potentially increasing the 
number of older individuals with comorbidities who are more likely to be admitted to the 
hospital with a less severe disease. We accounted for this in our analysis by adjusting for 
age, CCI, and prior-year health care visits, but residual confounding is always a concern. In 
addition, when calculating the tertile of prior-year health care visits, we could only access 
visits within the hospital study sites or their associated outpatient clinics, and the majority of 
individuals who had no visits did not get their regular care within these two systems. 
However, when the population was restricted to those who did get regular care at our study 
sites in a sensitivity analysis, the trends of increased severity among those with no prior-year 
visits remained.
In conclusion, we identified frailty and number of prior-year health care visits as predictors 
of all-cause and influenza-associated ARI severity. Our finding that vaccinated patients who 
received neuraminidase inhibitors had decreased LOS needs confirmation from future 
studies, but also adds to the evidence that administration of neuraminidase inhibitors to 
hospitalized patients reduces influenza severity and reinforces current treatment 
recommendations in the hospital [23,32–34].
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Table 1
Demographics and Outcomes of Hospitalized Adults with ARI by Influenza Status
Total N=1119 Influenza Positive N=216 Influenza Negative N=903 P Value3
Characteristics N (Column %) N (Column %) N (Column %)
Sex 0.68
 Male 501 (44.7%) 94 (43.5%) 407 (45.1%)
 Female 618(54.8%) 122 (56.5%) 496 (54.9%)
Age 0.44
 18–49 323 (28.9%) 67 (31.0%) 256 (28.3%)
 50–64 415 (37.1%) 72 (33.3%) 343 (38.0%)
 ≥65 381 (34.0%) 77 (35.7%) 304 (33.7%)
Race1 0.62
 White (Non-Hispanic) 583 (52.7%) 114 (54.0%) 469 (52.3%)
 Black (Non-Hispanic) 392 (35.4%) 76 (36.0%) 316 (35.3%)
 Other 132 (11.9%) 21 (10.0%) 111 (12.4%)
Site of Enrollment 0.47
 Hospital A 636 (56.8%) 118 (54.6%) 518 (57.4%)
 Hospital B 483 (43.2%) 98 (45.4%) 385 (42.6%)
Year 0.12
 2014–2015 664 (59.3%) 118 (54.6%) 546 (60.5%)
 2015–2016 455 (40.7%) 98 (45.4%) 357 (39.5%)
Charlson Score 0.01
 0 119 (10.6%) 33 (15.3%) 86 (9.5%)
 1 283 (25.3%) 62 (28.7%) 221 (24.5%)
 2 157 (14.0%) 32 (14.8%) 125 (13.8%)
 ≥3 560 (50.0%) 89 (41.2%) 471 (52.2%)
Frailty Score (median(IQR)) 0.25 (0.0–0.50) 0.40 (0.20–0.60) 0.04
BMI Category2 0.51
 <18.5 42 (3.9%) 4 (1.9%) 38 (4.3%)
 18.5–24.9 267 (24.7%) 53 (25.7%) 214 (24.5%)
 25–29.9 284 (26.3%) 53 (25.7%) 231 (26.4%)
 30–39.9 315 (29.1%) 65 (31.6%) 250 (28.6%)
 ≥40 173 (16.0%) 31 (15.1%) 142 (16.2%)
Number of Healthcare Visits (Tertiles) 0.61
 0 128 (11.4%) 28 (13.0%) 100 (11.1%)
 1 349 (31.2%) 72 (33.3%) 277 (30.7%)
 2 318 (28.4%) 60 (27.8%) 258 (28.6%)
 3 324 (29.0%) 56 (25.9%) 268 (29.7%)
Vaccination Status <0.01
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Total N=1119 Influenza Positive N=216 Influenza Negative N=903 P Value3
 Vaccinated 750 (67.0%) 113 (52.3%) 637 (70.5%)
 Unvaccinated 369 (33.0%) 103 (47.7%) 266 (29.5%)
Death 15 (1.3%) 2 (1.0%) 13 (1.4%) 0.56
ICU 126 (11.3%) 22 (10.2%) 104 (11.5%) 0.58
Invasive Ventilator 48 (4.3%) 10 (4.6%) 38 (4.2%) 0.78
LOS >8 Days 108 (9.7%) 19 (8.8%) 89 (9.9%) 0.63
30 day Readmission 167 (14.9%) 16 (7.4%) 151 (16.7%) <0.01
112 individuals have missing Race information
238 individuals have missing BMI information
3
P values are from chi square tests or Fisher’s exact tests when appropriate
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Table 2
Demographics and Outcomes of Enrolled Patients Hospitalized with Influenza A Associated ARI by Subtype
Total N=201 H3N2 N=111 H1N1N=90
Characteristics N (Column %) N (Column %) N (Column %) P Value3
Sex 0.20
 Male 90 (44.8%) 43 (48.7%) 43 (47.8%)
 Female 111 (55.2%) 68 (61.3%) 47 (52.2%)
Age 0.10
 18–49 y 62 (30.8%) 29 (26.1%) 33 (36.7%)
 50–64 y 68 (33.8%) 36 (32.4%) 32 (35.6%)
 ≥65 y 71 (35.3%) 46 (41.4%) 25 (35.2%)
Race1 0.22
 White (Not Hispanic) 106 (53.8%) 63 (57.3%) 43 (49.4%)
 Black 71 (36.0%) 34 (30.9%) 37 (42.5%)
 Other 20 (10.1%) 13 (11.8%) 7 (8.0%)
Site of Enrollment 0.29
 Hospital A 111 (55.2%) 65 (58.6%) 46 (51.1%)
 Hospital B 90 (44.8%) 46 (41.4%) 44 (48.9%)
Charlson Score 0.02
 0 31 (15.4%) 10 (9.0%) 21 (23.3%)
 1 59 (29.3%) 39 (35.1%) 20 (22.2%)
 2 27 (13.4%) 13 (11.7%) 14 (15.6%)
 ≥3 84 (41.8%) 49 (44.1%) 35 (38.9%)
Frailty Score (median(IQR)) 0.25 (0.0,0.40) 0.20 (0.0–0.5) 0.40 (0.0–0.40) 0.89
BMI Category2 0.11
 <18.5 4 (1.7%) 4 (3.6%) 0 (0.0%)
 18.5–24.9 47 (24.0%) 24 (21.8%) 23 (28.4%)
 25–29.9 49 (25.1%) 33 (30.0%) 16 (19.7%)
 ≥30 91 (49.2%) 49 (44.6%) 42 (51.9%)
Year <0.01
 2014–15 107 (53.2%) 107 (96.4%) 0 (0.0%)
 2015–16 94 (46.8%) 4 (3.6%) 90 (100.0%)
Total Number of Healthcare Visits In the Last Year (Tertiles) 0.05
 0 25 (12.4%) 8 (7.2%) 17 (18.9%)
 1 64 (31.8%) 34 (30.6%) 30 (33.3%)
 2 58 (28.9%) 34 (30.6%) 24 (26.7%)
 3 54 (26.9%) 35 (31.5%) 19 (21.1%)
Vaccination Status 0.02
 Vaccinated 106 (52.7%) 67 (60.4%) 39 (43.3%)
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Total N=201 H3N2 N=111 H1N1N=90
 Unvaccinated 95 (46.1%) 44(39.6%) 51 (56.7%)
Death 2 (1.0%) 1 (0.9%) 1 (1.1%) 1.00
ICU 20 (10.0%) 7 (6.3%) 13 (14.4%) 0.06
Invasive Ventilator 9 (4.5%) 1 (0.9%) 8 (8.9%) 0.01
LOS >8 Days 18 (9.0%) 5 (4.5%) 13 (14.4%) 0.02
30 day Readmission 16 (8.0%) 10 (9.0%) 6 (6.7%) 0.61
14 individuals are missing race information
210 individuals are missing BMI information
3
P values reflect results of Pearson Chi-square tests or Fisher’s exact test when appropriate. P values for continuous variables represent results of 
Wilcoxon tests
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Table 4
Demographics by Antiviral Prescription Timing Among Participants with Laboratory Confirmed Influenza
Timely Antivirals1 N=86 Late Antivirals N=61 No Antivirals N=69 P Value4
Characteristics N (Row %) N (Row %) N (Row %)
Sex 0.75
 Male 40 (42.6%) 26 (27.7%) 28 (29.8%)
 Female 46 (37.7%) 35 (28.7%) 41 (33.6%)
Age 0.31
 18–49 31 (46.3%) 21 (31.3%) 15 (22.4%)
 50–64 27 (37.5%) 21 (29.2%) 24 (33.3%)
 ≥65 28 (36.4%) 19 (24.7%) 30 (39.0%)
Race2 0.21
 White 51 (44.7%) 32 (28.1%) 31 (27.2%)
 Black 30 (39.5%) 19 (25.0%) 27 (35.5%)
 Other 4 (19.0%) 8 (38.1%) 9 (42.9%)
Site of Enrollment 0.01
 Hospital A 54 (45.8%) 37 (31.4%) 27 (22.9%)
 Hospital B 32 (32.6%) 24 (24.5%) 42 (42.9%)
Year 0.24
 2014–2015 42 (35.6%) 33 (28.0%) 43 (36.4%)
 2015–2016 44 (44.9%) 28 (28.6%) 26 (26.5%)
Influenza Type/Subtype 0.23
 A/H3N2 37 (33.3%) 35 (31.5%) 39 (35.1%)
 A/H1N1 42 (46.7%) 24 (26.7%) 24 (26.7%)
 B 7 (46.7%) 2 (13.3%) 6 (40.0%)
Charlson Score 0.36
 0 17 (51.5%) 8 (24.2%) 8 (24.2%)
 1 17 (27.4%) 21 (33.9%) 24 (38.7%)
 2 14 (43.7%) 9 (28.1%) 9 (28.1%)
 ≥3 38 (42.7%) 23 (25.8%) 28 (31.5%)
Frailty Score 0.20 (0.0–0.40) 0.40 (0.20–0.60) 0.40 (0.20–0.60) 0.20
Obese3 0.22
 Yes 39 (40.6%) 31 (32.3%) 26 (27.1%)
 No 43 (39.1%) 26 (23.6%) 41 (37.3%)
Number of Health Care Visits (Tertiles) 0.52
 0 11 (39.3%) 8 (28.6%) 9 (32.1%)
 1 28 (38.9%) 15 (20.8%) 29 (40.3%)
 2 23 (38.3%) 21 (35.0%) 16 (26.7%)
 3 24 (42.9%) 17 (30.4%) 15 (26.8%)
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Timely Antivirals1 N=86 Late Antivirals N=61 No Antivirals N=69 P Value4
Characteristics N (Row %) N (Row %) N (Row %)
Vaccination Status 0.85
 Yes 46 (40.7%) 30 (26.6%) 37 (32.7%)
 No 40 (38.8%) 31 (30.1%) 32 (31.1%)
Length of Stay (median, IQR) 2.0 (2.0–4.0) 3.0 (2.0–5.0) 3.0 (2.0–5.0) 0.17
1
Timely antivirals refers to antivirals within 2 days of symptom onset
25 individuals are missing race information
310 individuals are missing BMI information
4
P values are from chi square tests or Fisher’s exact tests when appropriate
Epidemiol Infect. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Segaloff et al. Page 18
Ta
bl
e 
5
H
az
ar
ds
 o
f D
isc
ha
rg
e 
Re
la
te
d 
to
 A
nt
iv
ira
l T
re
at
m
en
t T
im
in
g
O
ve
ra
ll 
(N
=2
01
)
Va
cc
in
at
ed
 (N
=1
06
)
U
nv
a
cc
in
at
ed
 (N
=9
5)
Pr
ed
ic
to
rs
H
az
ar
d 
R
at
io
 (9
5%
 C
I)
P 
Va
lu
e
H
az
ar
d 
R
at
io
 (9
5%
 C
I)
P 
Va
lu
e
H
az
ar
d 
R
at
io
 (9
5%
 C
I)
P 
Va
lu
e
A
nt
iv
ir
al
 T
re
a
tm
en
t
1.
1 
(0.
8, 
1.5
)
0.
44
1.
6 
(1.
0, 
2.4
)
0.
04
0.
9 
(0.
5, 
1.4
)
0.
52
Fr
ai
lty
 S
co
re
0.
5 
(0.
3, 
1.0
)
0.
04
0.
6 
(0.
3, 
1.3
)
0.
17
0.
5 
(0.
2, 
1.2
)
0.
11
To
ta
l V
isi
ts
 (T
er
til
es
)
Te
rt
ile
 0
re
f
R
ef
re
f
Te
rt
ile
 1
1.
6 
(1.
0, 
2.7
)
0.
05
0.
5 
(0.
1, 
1.6
)
0.
23
1.
6 
(0.
9, 
2.9
)
0.
09
Te
rt
ile
 2
1.
3 
(0.
8, 
2.1
)
0.
32
0.
3 
(0.
1, 
1.0
)
0.
05
1.
3 
(0.
7, 
2.4
)
0.
40
Te
rt
ile
 3
1.
5 
(0.
9, 
2.4
)
0.
13
0.
4 
(0.
2, 
1.2
)
0.
09
1.
6 
(0.
8, 
3.5
)
0.
21
1 M
od
el
s c
on
ta
in
 a
ll 
pr
ed
ic
to
rs
 in
 th
e 
ta
bl
e
Epidemiol Infect. Author manuscript; available in PMC 2019 February 01.
